EUCODIS appoints Dr. David Rozzell and Dr. Ulf Bethke to Realigned Advisory Board
EUCODIS Bioscience announced the appointment of two seasoned biotechnology executives to its Advisory Board. The new appointees are Dr. David Rozzell, founder of BioCatalytics (now Codexis) and currently CEO of Solidus Biosciences, and Dr. Ulf Bethke, COO of Miltenyi Biotec. Dr. Thomas Moser, Pontis Capital, and Harald Schuerz, Wiener Wachstumsfonds, will continue to serve on the realigned Advisory Board.
With its current members, EUCODIS Bioscience’s Advisory Board will focus on providing guidance and advice in the areas of strategy, market and organization, strengthening the skills and experience of EUCODIS Bioscience’s management team.
Dr. David Rozzell is President and CEO of Solidus Biosciences, a company providing research and analytical services to the pharmaceutical and cosmetics industry, enhancing their development productivity. Prior to joining Solidus as CEO, he was the Founder and CEO of enzyme developer BioCatalytics, which he grew to a leader in its field until the company was successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr. Rozzell was President and COO of Exogene.
Dr. Ulf Bethke is Chief Operating Officer of Miltenyi Biotec, one of Germany’s most successful biotechnology companies. Before joining Miltenyi Biotec in 1994, he was responsible for the development and production of therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.
Dr. Thomas Moser is Managing Partner at Pontis Capital, an Austrian venture capital company. He has 10 years of experience as an investment manager, overseeing the whole investment life-cycle, from deal acquisition through active management of portfolio companies to financing and implementation of the exit strategy.
Harald Schuerz is CEO of Wiener Wachstumsfonds, an Austrian venture capital fund focusing on innovative, fast growing companies. Before joining Athena, he held executive positions at leading Austrian banks where he was responsible for venture capital investments and international financing.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
